Discrepancies between use of antihypertensive drugs and guidelines indications: Pharmacoeconomic implications

Journal of Human Hypertension

Volumn 19, Issue 10, 2005, Pages 819-822

  Robbiano, L ^a   Martelli, A ^a   Brambilla, G ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; METHYLDOPA; METOPROLOL; MINOXIDIL; THIAZIDE DIURETIC AGENT;

ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; DRUG USE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; ITALY; MONOTHERAPY; MORBIDITY; PRACTICE GUIDELINE; PRESCRIPTION; RISK REDUCTION; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; DRUG COSTS; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES;

EID: 27144530299     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001900     Document Type: Article

References (11)

1. ISTAT - (Istituto Nazionale di Statistica). Il quadro evolutivo della mortalità per causa in Italia: Anni 1991, 1994, 1997. http://www.istat.it.2003.
2. Farmindustria. Indicatori Farmaceutici. Spesa per anti-ipertensivi in Italia nel 2003. http://www.farmindustria.it.2004.
3. Packer M et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.
4. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
5. Chobanian AV et al. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.
6. Williams B et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
7. Guidelines Committee. 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
8. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
9. Tierney Jr LM, McPhee SJ, Papadakis MA. Current Medical Diagnosis & Treatment 2004, 43rd edn, Lange Medical Books/McGraw-Hill: New York, 2004, pp 401-427.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-2997.
11. Psaty BM et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003; 289: 2534-2544.